Form 4: Cidara Therapeutics Director Acquires 20,500 Stock Options

Director Daniel D. Burgess acquired 20,500 stock options in Cidara Therapeutics, Inc. on December 17, 2024.

Summary

• Daniel D. Burgess, a director at Cidara Therapeutics, Inc., acquired 20,500 stock options on December 17, 2024.
• The options have an exercise price of $22.81.
• The options vest in 36 equal monthly installments starting from December 17, 2024.
• The options expire on December 16, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant to a director. It is neither particularly positive nor negative, but it does indicate that a director has a vested interest in the company's performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of 36 months is also a typical vesting period for stock options.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, director, insider trading, Cidara Therapeutics, CDTX, equity, vesting